INIS
patients
100%
tissues
67%
anticoagulants
61%
thrombin
49%
cancer
44%
risks
40%
plasma
35%
drugs
33%
atherosclerosis
32%
proteins
29%
interactions
29%
lung cells
28%
thrombosis
27%
levels
26%
cardiovascular diseases
22%
therapy
21%
heparin
21%
monitoring
19%
concentration
18%
women
18%
length
18%
comparative evaluations
17%
range
17%
data
16%
antibodies
16%
vitamin k
15%
control
15%
sex
15%
myocardial infarction
15%
fibrin
14%
Keyphrases
Tissue Factor Pathway inhibitor-2 (TFPI-2)
62%
Direct Oral Anticoagulants
46%
Platelets
28%
Non-small Cell Lung Cancer (NSCLC)
28%
Drug Interactions
28%
Thrombin Generation
27%
Tissue Factor
26%
Endogenous Thrombin Potential
20%
Procoagulant State
19%
Cardiovascular Risk
18%
Arterial Thrombosis
17%
Cardiovascular Disease
17%
Myocardial Infarction
16%
Anticoagulant Therapy
16%
Vitamin K Antagonists
16%
Hypercoagulability
15%
Evolving Data
14%
Young Women
14%
Early Atherosclerosis
14%
In Cancer
14%
Remission
14%
Cardiovascular Complications
14%
Patients with Cancer
14%
Venous Thromboembolism Prevention
14%
Risk Study
14%
Elderly Patients
14%
Procalcitonin
14%
Apixaban
14%
Fibrin Formation
14%
Healthy Volunteers
14%
Medicine and Dentistry
Tissue Factor Pathway Inhibitor
48%
Direct Oral Anticoagulant
32%
Thrombin
26%
Venous Thromboembolism
25%
Procoagulant
23%
Antithrombotic
20%
Atherosclerosis
18%
Vitamin K Antagonist
16%
Anticoagulant Therapy
16%
Myocardial Infarction
15%
Protein S
14%
Blood Vessel Calcification
14%
Cardiovascular Disease
14%
Malignant Neoplasm
14%
Procalcitonin
14%
Cohort Study
14%
Apixaban
14%
Warfarin
14%
Platelet
14%
Heparin
14%
Non Small Cell Lung Cancer
14%
ANCA Associated Vasculitis
14%
Alectinib
14%
Volunteer
14%
Lacunar Stroke
14%
COVID-19
14%
Drug Interaction
14%
Thromboplastin
12%
Thrombin Antithrombin Complex
10%
Inhibitor Protein
8%